Corient Private Wealth LLC Grows Position in Encompass Health Co. (NYSE:EHC)

Corient Private Wealth LLC lifted its holdings in shares of Encompass Health Co. (NYSE:EHCFree Report) by 187.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 17,077 shares of the company’s stock after buying an additional 11,130 shares during the period. Corient Private Wealth LLC’s holdings in Encompass Health were worth $1,139,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of EHC. Benjamin Edwards Inc. boosted its position in Encompass Health by 3.8% in the fourth quarter. Benjamin Edwards Inc. now owns 3,885 shares of the company’s stock worth $259,000 after purchasing an additional 142 shares during the last quarter. Treasurer of the State of North Carolina boosted its position in Encompass Health by 0.5% in the third quarter. Treasurer of the State of North Carolina now owns 48,339 shares of the company’s stock worth $3,246,000 after purchasing an additional 231 shares during the last quarter. Linden Thomas Advisory Services LLC boosted its position in Encompass Health by 1.7% in the fourth quarter. Linden Thomas Advisory Services LLC now owns 15,473 shares of the company’s stock worth $1,032,000 after purchasing an additional 253 shares during the last quarter. Handelsbanken Fonder AB boosted its position in Encompass Health by 1.9% in the fourth quarter. Handelsbanken Fonder AB now owns 15,953 shares of the company’s stock worth $1,064,000 after purchasing an additional 300 shares during the last quarter. Finally, Inceptionr LLC boosted its position in Encompass Health by 3.5% in the fourth quarter. Inceptionr LLC now owns 9,029 shares of the company’s stock worth $602,000 after purchasing an additional 306 shares during the last quarter. 97.25% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Encompass Health

In other news, Director Greg D. Carmichael acquired 2,000 shares of the firm’s stock in a transaction dated Friday, May 3rd. The shares were acquired at an average cost of $83.73 per share, with a total value of $167,460.00. Following the acquisition, the director now directly owns 17,050 shares of the company’s stock, valued at $1,427,596.50. The transaction was disclosed in a document filed with the SEC, which is available at this link. In related news, insider Elissa Joy Charbonneau sold 10,000 shares of the stock in a transaction on Friday, May 24th. The stock was sold at an average price of $85.02, for a total transaction of $850,200.00. Following the sale, the insider now owns 18,594 shares in the company, valued at approximately $1,580,861.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Greg D. Carmichael purchased 2,000 shares of the firm’s stock in a transaction that occurred on Friday, May 3rd. The shares were bought at an average price of $83.73 per share, for a total transaction of $167,460.00. Following the acquisition, the director now directly owns 17,050 shares in the company, valued at approximately $1,427,596.50. The disclosure for this purchase can be found here. Insiders have sold 69,519 shares of company stock valued at $5,816,091 in the last ninety days. Corporate insiders own 2.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. Raymond James reissued a “strong-buy” rating and issued a $95.00 target price (up from $85.00) on shares of Encompass Health in a research report on Friday, April 26th. Mizuho lifted their price objective on Encompass Health from $93.00 to $95.00 and gave the company a “buy” rating in a research report on Thursday, April 25th. Barclays lifted their price objective on Encompass Health from $101.00 to $108.00 and gave the company an “overweight” rating in a research report on Thursday, April 25th. Truist Financial lifted their price objective on Encompass Health from $82.00 to $86.00 and gave the company a “buy” rating in a research report on Friday, February 9th. Finally, Royal Bank of Canada lifted their price objective on Encompass Health from $83.00 to $95.00 and gave the company an “outperform” rating in a research report on Wednesday, May 22nd. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $92.00.

Read Our Latest Report on Encompass Health

Encompass Health Stock Up 0.9 %

Shares of EHC opened at $86.39 on Monday. The business’s 50 day moving average is $83.02 and its 200 day moving average is $74.82. The company has a market capitalization of $8.70 billion, a PE ratio of 23.35, a price-to-earnings-growth ratio of 1.35 and a beta of 0.92. Encompass Health Co. has a 12-month low of $57.55 and a 12-month high of $87.94. The company has a current ratio of 1.37, a quick ratio of 1.37 and a debt-to-equity ratio of 1.14.

Encompass Health (NYSE:EHCGet Free Report) last released its quarterly earnings data on Wednesday, April 24th. The company reported $1.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.93 by $0.19. The business had revenue of $1.32 billion for the quarter, compared to the consensus estimate of $1.27 billion. Encompass Health had a return on equity of 18.01% and a net margin of 7.60%. The company’s revenue was up 13.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.88 EPS. Research analysts expect that Encompass Health Co. will post 4.1 earnings per share for the current fiscal year.

Encompass Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, July 15th. Stockholders of record on Monday, July 1st will be issued a dividend of $0.15 per share. The ex-dividend date is Monday, July 1st. This represents a $0.60 annualized dividend and a dividend yield of 0.69%. Encompass Health’s dividend payout ratio (DPR) is 16.22%.

Encompass Health Company Profile

(Free Report)

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.

Read More

Want to see what other hedge funds are holding EHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Encompass Health Co. (NYSE:EHCFree Report).

Institutional Ownership by Quarter for Encompass Health (NYSE:EHC)

Receive News & Ratings for Encompass Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Encompass Health and related companies with MarketBeat.com's FREE daily email newsletter.